Innovation plays a key role in The ALS Association’s fight to develop treatments and a cure for ALS and to empower people living with the disease to live their lives to the fullest. During June and July, we are celebrating some of the key innovations helping us change the nature of ALS forever.
In the May 2018 issue of Frontiers in Neuroscience, current The ALS Association-funded researchers, Drs. J. Paul Taylor and Maria Purice of St. Jude Children’s Research Hospital in Memphis, published a comprehensive mini-review describing disease pathways that cause ALS, with a focus on mutations in RNA-binding proteins.
Many recent innovations in ALS animal and cells models that were instrumental in understanding the role of RNA-binding proteins in ALS are described.
Dr. Purice is a current Milton Safenowitz fellow who is currently studying how molecular pathways lead to both inherited (in which researchers have identified mutated ALS genes) and sporadic (non-inherited) forms of ALS, with a focus on RNA-binding protein, TDP-43.
In this review, Drs. Purice and Taylor do a deep dive into how disturbances in RNA-binding proteins, including TDP-43, cause ALS.
RNA-binding proteins are a large class of proteins that play a role in RNA metabolism. They are among the most abundant proteins in cells that reside both in the cell’s nucleus and surrounding cytoplasm.
Over the last decade, mutations in RNA-binding proteins have been linked to ALS and frontotemporal dementia (FTD), including TDP-43, FUS, hnRNPs A1 and A2B1, MATR3, and TIA1.
Learn more about RNA-binding proteins, with a special focus on the above proteins’ normal function, and what happens in cells when those proteins’ normal function is disrupted, leading to characteristics of ALS.
Donate now to support projects like this one and other innovative, collaborative work that is helping to advance research and care for people living with ALS and their families.
Don’t miss out on doubling your impact! This is a critical time to donate since our corporate partner, Biohaven Pharmaceuticals, is matching all gifts up to a total of $25,000! Biohaven is committed to supporting innovation to help improve the lives of all people impacted by ALS.
To learn more about Biohaven’s commitment to advances in ALS and other neurological diseases, click here.
Purice MD and Taylor JP (2018) Linking hnRNP Function to ALS and FTD Pathology. Front. Neurosci. 12:236. Doi: 10.3389/fnins.2018.00326
*This publication is open access.